Abstract:Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-ε-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way toward surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5% ± 0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8° ± 2.3, PCL-PEG: 61.2° ± 7.5) versus those without (PLLA: 79.5° ± 3.2, PCL: 76.4° ± 10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent in vitro cyto- and hemocompatibility.

Degradability of the Linear Azo Polymer Conjugated 5,5′‐azodisalicylic Acid Segment in the Main Chain for Colon‐specific Drug Delivery

SYNTHESIS AND IN VITRO BIODEGRADATION OF AZO POLYMER FOR COLON-SPECIFIC DRUG DELIVERY

Linear Azo Polymer Containing Conjugated 5,5′-Azodisalicylic Acid Segments in the Main Chain: Synthesis, Characterization, and Degradation

Preparation, Characterization and Degradation Characteristics of Polyanhydrides Containing Poly(Ethylene Glycol)

SYNTHESIS AND CHARACTERIZATION OF A ENZYME SPECIFIC DEGRADED AMPHIPHILIC COPOLYMER

Sustained release of 5-aminosalicylic acid from azoreductase-responsive polymeric prodrugs for prolonged colon-targeted colitis therapy

Preparation and in vitro release of 5-aminosalicylic acid time-controlled release pellets for colon-specific delivery

Clickable,Oxidation-Responsive and Enzyme-Degradable Polypeptide:Synthesis,Characterization and Side Chain Modification

Preparation and Evaluation of Colon Adhesive Pellets of 5-Aminosalicylic Acid.

Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications

Preparation of 5-Amino Salicylic Acid(5-Asa) Colon-Specific Targeting Enzyme-Controlled Release Pellets and Its in Vitro Release

Preparation and properties of a biodegradable polymer as a novel drug delivery system

Saloplastics based on protein-peptides complexes immobilizing organic molecules in gastrointestinal drug delivery for ulcerative colitis treatment

Preparation and Properties of A Ph Sensitive Carrier Based on Three Kinds of Polymer Blend to Control the Release of 5-Amino Salicylic Acid

Synthesis and Characterization of a Biodegradable Amphiphilic Copolymer Based on Branched Poly(ϵ‐caprolactone) and Poly(ethylene Glycol)

Influence of the coating formulation on enzymatic digestibility and drug release from 5-aminosalicylic acid pellets coated with mixtures of high-amylose starch and Surelease® intended for colon-specific drug delivery

Identification of a New Azoreductase Driven Prodrug from Bardoxolone Methyl and 5-Aminosalicylate for the Treatment of Colitis in Mice.

Redox-Sensitive Linear and Cross-Linked Cystamine-Based Polymers for Colon-Targeted Drug Delivery: Design, Synthesis, and Characterisation

Enzyme and PH responsive 5-flurouracil (5-FU) loaded hydrogels based on olsalazine derivatives for colon-specific drug delivery

Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice.

Synthesis and Properties of Degradable Hydrogels of Konjac Glucomannan Grafted Acrylic Acid for Colon-Specific Drug Delivery